Related Experiment Videos
Thromboxane biosynthesis and platelet function in type II diabetes mellitus.
1Department of Medicine, University of Chieti, Rome, Italy.
The New England Journal of Medicine
|June 21, 1990
Summary
Patients with type II diabetes exhibit higher thromboxane production, indicated by increased urinary 11-dehydro-thromboxane B2 excretion. Improved glycemic control and low-dose aspirin significantly reduce thromboxane metabolite levels.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Biochemistry
Background:
- Platelet hyperreactivity is a concern in diabetes mellitus.
- Increased thromboxane production may contribute to platelet issues in diabetics.
Purpose of the Study:
- To compare thromboxane metabolite excretion and platelet function in Type II diabetes patients versus healthy controls.
- To investigate the effects of metabolic control and aspirin on thromboxane production.
Main Methods:
- Measured urinary 11-dehydro-thromboxane B2 excretion in 50 Type II diabetes patients and 32 controls.
- Assessed fractional conversion of thromboxane B2 and the impact of insulin therapy and low-dose aspirin.
Main Results:
- Diabetic patients showed significantly higher urinary 11-dehydro-thromboxane B2 levels (P < 0.001).
- Insulin therapy reduced metabolite levels by ~50%; low-dose aspirin reduced excretion by ~80%.
- Fractional conversion rates of thromboxane B2 did not differ between groups.
Conclusions:
- Elevated thromboxane biosynthesis is present in Type II diabetes patients with macrovascular disease.
- Thromboxane metabolite levels are sensitive to glycemic control and aspirin therapy, suggesting a platelet origin.